{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=41&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Miami",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 12560,
    "total_pages": 1256,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=42&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=40&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T22:46:53.949Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02601703",
      "title": "To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Ointment 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Protopic® ointment, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo of Tacrolimus Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glenmark Pharmaceuticals Ltd. India",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1110,
      "start_date": "2015-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 60,
      "location_summary": "Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601703"
    },
    {
      "nct_id": "NCT02512042",
      "title": "Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Test-Brinzolamide 1% Ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Reference-Brinzolamide 1% Ophthalmic suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 973,
      "start_date": "2015-04",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 10,
      "location_summary": "Newport Beach, California • Largo, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02512042"
    },
    {
      "nct_id": "NCT01114269",
      "title": "PRE-DETERMINE Cohort Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease",
        "Left Ventricular Dysfunction",
        "Sudden Cardiac Death"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5764,
      "start_date": "2007-07",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 86,
      "location_summary": "Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 76 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01114269"
    },
    {
      "nct_id": "NCT05662306",
      "title": "C-Cog in Early Course Schizophrenia Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole Lauroxil",
          "type": "DRUG"
        },
        {
          "name": "Computerized cognitive and functional skills training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-01-23",
      "completion_date": "2025-03-03",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662306"
    },
    {
      "nct_id": "NCT01576484",
      "title": "Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Heterozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matched to Alirocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-02-28",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 11,
      "location_summary": "Mission Viejo, California • Newport Beach, California • Thousand Oaks, California + 8 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576484"
    },
    {
      "nct_id": "NCT04501952",
      "title": "Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "RDV",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match RDV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 584,
      "start_date": "2020-09-18",
      "completion_date": "2021-05-06",
      "has_results": true,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 92,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Eureka, California + 78 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Eureka",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501952"
    },
    {
      "nct_id": "NCT07142252",
      "title": "Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Rezpegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 66,
      "start_date": "2026-05-14",
      "completion_date": "2028-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142252"
    },
    {
      "nct_id": "NCT00335738",
      "title": "Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intraocular Retinoblastoma"
      ],
      "interventions": [
        {
          "name": "liposomal vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "Up to 6 Years"
      },
      "enrollment_count": 331,
      "start_date": "2005-12",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335738"
    },
    {
      "nct_id": "NCT05827926",
      "title": "A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 1758,
      "start_date": "2023-04-14",
      "completion_date": "2024-12-03",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 69,
      "location_summary": "Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827926"
    },
    {
      "nct_id": "NCT03118765",
      "title": "Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "GSP304 (tiotropium bromide) Inhalation Solution",
          "type": "DRUG"
        },
        {
          "name": "GSP304 Placebo Inhalation Solution",
          "type": "DRUG"
        },
        {
          "name": "Spiriva® Respimat® inhalation spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glenmark Specialty S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 155,
      "start_date": "2017-03-24",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-11-18T22:46:53.949Z",
      "location_count": 25,
      "location_summary": "Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03118765"
    }
  ]
}